Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia

BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Epidemiol
Autores principales: Hagberg, Katrina Wilcox, Divan, Hozefa A, Fang, Shona C, Nickel, J Curtis, Jick, Susan S
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312705/
https://ncbi.nlm.nih.gov/pubmed/28228662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S124674
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares